Anti-Shiga toxin monoclonal antibodies - Taro Pharmaceuticals
Alternative Names: Anti-Stx monoclonal antibodies; c-Stx1; c-Stx1/c-Stx2; c-Stx2; caStx1; caStx1/caStx2; caStx2; Shigamab; ShigamabsLatest Information Update: 22 Feb 2023
At a glance
- Originator Sunol Molecular Corporation; Uniformed Services University of the Health Sciences
- Developer BELLUS Health; Taro Pharmaceuticals Inc
- Class Antibacterials; Monoclonal antibodies
- Mechanism of Action Bacterial toxin inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Haemolytic uraemic syndrome; Shiga-toxigenic Escherichia coli infections
Most Recent Events
- 22 Feb 2023 Discontinued - Preclinical for Haemolytic uraemic syndrome in USA (IV) (Taro Pharmaceuticals pipeline, February 2023)
- 28 Jun 2018 No recent reports of development identified for preclinical development in Haemolytic-uraemic-syndrome in USA (IV, Infusion)
- 16 Mar 2017 Thallion Pharmaceuticals including anti-Shiga toxin monoclonal antibodies acquired by Taro Pharmaceuticals from Bellus Health